铁调素在慢性肾脏病发生及发展中的研究进展  

Research progress of Hepcidin in the occurence and development of chronic kidney disease

作　　者：王富菊 郁丽霞[1] WANG Fu-ju;YU Li-xia(Department of Nephrology,Kunshan Hospital Affiliated to Jiangsu University,Jiangsu Province,Kunshan 215300,China)

机构地区：[1]江苏大学附属昆山医院肾脏内科,江苏昆山215300

出　　处：《中国当代医药》2021年第17期43-47,共5页China Modern Medicine

摘　　要：慢性肾脏病(CKD)患者常常合并多种并发症,随着CKD的发生发展,肾性贫血(RA)的发生率逐步升高。RA不仅延长CKD患者的住院时间,还影响患者的生存率,因此对CKD患者进行贫血治疗则尤为关键。引起RA的因素有多种,其中最主要因素是红细胞生成素(EPO)不足及铁代谢异常,铁代谢异常导致铁绝对量不足或相对量不足,而铁调素在铁代谢异常中发挥非常重要的调节作用。本文综述铁调素的功能、相关信号通路及铁调素在CKD发生发展进程中的关系,为临床治疗RA提供依据。Chronic kidney disease(CKD)patients often have multiple complications,and the incidence of renal anemia(RA)gradually increases with the course of CKD.RA not only prolongs the hospital stay of CKD patients,but also affects the survival rate of patients.Therefore,treatment of anemia for CKD patients is particularly critical.There are many factors that cause RA.The most important factor is the lack of erythropoietin(EPO)and abnormal iron metabolism.Abnormal iron metabolism leads to insufficient or relative lack of iron.Hepcidin plays an important role in the regulation of iron metabolism abnormalities.This article mainly reviews the function of Hepcidin,related signal pathways and the relationship of Hepcidin in the occurrence and development of CKD,and provides a basis for clinical treatment of RA.

关 键 词：铁调素 慢性肾脏病 肾性贫血 红细胞生成素 

分 类 号：R692[医药卫生—泌尿科学]